Enzyre B.V.

Enzyre B.V. is a Dutch diagnostics company focused on personalized medicine, particularly in blood coagulation management. Founded in 2016 as a spin-off from Radboud University Medical Center, Enzyre aims to provide laboratory-quality testing directly to patients, allowing for real-time monitoring of coagulation status outside traditional clinical environments. The company's flagship technology, EnzyPad, is a point-of-care diagnostic system that enables patients, especially those with hemophilia, to conveniently monitor their blood coagulation at home. It utilizes microfluidic cartridges for painless blood sampling and offers real-time data transfer to healthcare professionals, enhancing telemedicine and personalized treatment adjustments. Enzyre's first commercial product, Hemophilia EnzyCard, supports hemophilia A patients in managing their condition through frequent and accurate coagulation testing. Enzyre's solutions are designed for patients with hemophilia and other coagulation disorders, as well as healthcare providers and clinical teams. The company has secured significant funding to further develop its technology and expand into new diagnostic applications, all while being led by experienced professionals in the field.

• Employees 15
• Founded 2016
• Annual Revenue $4000000
• Total Funding $11880204